Author

Vincent Roux-Portalez

Observed names: Roux-Portalez, Vincent, V. Roux-Portalez

Observed institutions: Inserm, Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier

OpenAlex ID: A5114789366

Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches

2024 · Daouda Abba Moussa, Mario Vazquez, et al. · Emerging Microbes & Infections · 4

Abstract 4347: A first-in-class bifunctional anti-TRPV6 antibody turns "cold" tumors "hot"

2026 · Lindsay B. Alcaraz, Margaux Maurel, et al. · Cancer Research

9P Development of a tumor-specific anti-TRPV6 therapeutic antibody in metastatic prostate cancer indication

2026 · T. Mangeat, L. Alcaraz, et al. · ESMO Open

8P Tumor-specific anti-CD30 ADC limits sCD30 sink effects and improves in-vivo efficacy compared to brentuximab vedotin

2026 · B. Gouyou, L. Alcaraz, et al. · ESMO Open

Abstract 4770: First-in-class anti-TRPV6 antibody as a new therapeutic agent in cancer

2025 · Lindsay B. Alcaraz, Vincent Roux-Portalez, et al. · Cancer Research

Works count: 6

Citation count: 4

H-index: 1

I10-index: